Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership


All
13F
13D/G
Other

Silence Therapeutics plc (SLN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and operating results together with our unaudited financial statements as of and for the three and six months ended June 30, 2023 and the related notes to those unaudited condensed consolidated financial statements included as Exhibit 99.1 to this Report on Form 6-K, as well as our audited consolidated financial statements and related notes as disclosed in our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 15, 2023. The statements in this discussion with respect to our plans and strategy for our business, including expectations regarding our future liquid..."
08/14/2023 SC 13D/A Griffiths Richard Ian reports a 26.6% stake in Silence Therapeutics plc
08/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
07/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Inquiries: Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications [email protected] Tel: +1 637-3208 About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high ..."
07/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
05/04/2023 6-K Quarterly results
05/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Inquiries: Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications [email protected] Tel: +1 637-3208 About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high leve..."
04/27/2023 6-K Quarterly results
03/28/2023 6-K Quarterly results
03/15/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
02/14/2023 SC 13G/A TCG Crossover GP I, LLC reports a 5.9% stake in Silence Therapeutics plc
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates 12 January 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN , an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today provided the following SLN360 and SLN124 program updates during a presentation at the 41st Annual J.P. Morgan Healthcare Conference: SLN360 for cardiovascular disease • The first subjects have been dosed in the SLN360 phase 2 study in high-risk atherosclerotic cardiovascular disease . The Company plans to complete enrollment in the study in the fourth quarter of 2023. More information on the trial can be found here. • Silence expects data from the ongoing phase 1 multiple dose study ..."
11/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period 5 November 2022 Silence Therapeutics plc, Nasdaq: SLN , an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today presented data from an analysis of its APOLLO phase 1 single dose study of SLN360, an investigational short interfering ribonucleic acid , in healthy adults with high lipoprotein ”), a key genetic risk factor for heart disease, at the American Heart Association 2022 Annual Meeting. The moderated poster entitled, “Time Averaged Lipoprotein Reduction with SLN360, A Novel SiRNA Targeting Lp in Healthy Adults with Elevated Lp,” assessed Lp levels of pa..."
10/20/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
09/29/2022 6-K Quarterly results
08/22/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/19/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/16/2022 6-K Quarterly results
08/12/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Silence Therapeutics Announces Pricing of Underwritten Offering LONDON, August 11, 2022 - Silence Therapeutics plc , a leader in the discovery, development and delivery of novel short interfering ribonucleic acid therapeutics for the treatment of diseases with significant unmet medical need, today announced the pricing of an underwritten offering of 5,950,000 American Depositary Shares , each representing three ordinary shares, at a price of $9.50 per ADS, for aggregate gross proceeds of approximately $56.5 million, before deducting underwriting discounts and commissions and other offering expenses. All of the ADSs are being offered by Silence. The offering is expected to close on or about August 16, 2022, subject to customary closing conditions. Silence intends to use the net proceeds of ..."
08/11/2022 6-K Quarterly results
07/20/2022 SC 13D/A Griffiths Richard Ian reports a 28.4% stake in Silence Therapeutics plc
06/15/2022 SC 13D Griffiths Richard Ian reports a 27% stake in Silence Therapeutics plc
06/14/2022 6-K Quarterly results
05/16/2022 6-K Quarterly results
05/16/2022 6-K Quarterly results
04/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration"
04/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"SLN360 reduced Lp – a key genetic risk factor for heart disease - by up to 98% with reductions of up to 81% persisting at 150 days – Results were simultaneously published in The Journal of the American Medical Association 3 April 2022 Silence Therapeutics plc, Nasdaq: SLN , a leader in the discovery, development and delivery of novel short interfering ribonucleic acid therapeutics for the treatment of diseases with significant unmet medical need, today presented detailed results from its phase 1 APOLLO trial that showed SLN360, an investigational siRNA, reduced levels of lipoprotein ”), an important genetic risk factor for heart disease, by up to 98% in healthy adults with high Lp. Findings from the “APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipop..."
03/23/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501 Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1study expected to begin in the first half of 2022"
03/17/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
02/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer Mark Rothera steps down as President and CEO"
02/14/2022 SC 13G Quested Robert reports a 7.8% stake in Silence Therapeutics plc
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy